Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | COASY | Q13057 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14222708 | 0.86 | NUDT1 (0.51) | NUDT1GRIN1GRIN2BATR | |
| SCHEMBL1202374 | 0.78 | PKN1 (0.61) | PARP1PLA2G2AALOX15PTGS2 | |
| Methyl Carbamate SCHEMBL6323881 | 0.77 | ALDH1A1 (0.68) | NUDT1 | |
| SCHEMBL11176777 | 0.76 | NUDT1 (0.43) | PARP1NUDT1CHEK1 | |
| Carbamic Acid SCHEMBL6323883 | 0.74 | ALDH1A1 (0.54) | PARP1NUDT1 | |
| SCHEMBL4629094 | 0.73 | PARP1 (0.47) | PARP1 | |
| SCHEMBL6842051 | 0.73 | PARP1 (0.69) | PARP1 | |
| SCHEMBL1193115 | 0.72 | PARP1 (0.54) | PARP1NUDT1 | |
| SCHEMBL24112332 | 0.72 | PKN1 (0.61) | PARP1NUDT1 | |
| SCHEMBL15113089 | 0.72 | PARP1 (0.49) | PARP1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-09-01 | — | — | US | disclosed |
| US-6900235-B1 | Benzimidazole compounds, and pharmaceutical compositions and unit dosages thereof | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-6864275-B1 | Anticancer agents; viricides | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-03-08 | — | — | US | disclosed |
| US-6710065-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER OR A VIRAL INFECTION | UAF TECHNOLOGIES AND RESEARCH, LLC | 2004-03-23 | — | — | US | disclosed |
| US-6482843-B1 | Compounds and methods for use thereof in the treatment of cancer or viral infections | THE PROCTER & GAMBLE COMPANY | 2002-11-19 | — | — | US | disclosed |
| US-6423735-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTER & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6423736-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTOR & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6420411-B1 | BENZIMIDAZOLE DERIVATIVES USED TO TREAT MELANOMA, LEUKEMIA, AND COLON, BREAST, LUNG, PANCREATIC, OVARIAN, AND PROSTATE CANCER; USED TO TREAT HIV; IMPROVED WATER SOLUBILITY | THE PROCTER & GAMBLE COMPANY | 2002-07-16 | — | — | US | disclosed |
| US-6407131-B1 | 5-CARBONYLOXY-1H-BENZIMIDAZOLE-2-CARBAMATE DERIVATIVES | THE PROCTER & GAMBLE COMPANY | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | PAICS, PIGO, BAD | PARP1 1133/4885NUDT1 26/4885CHEK1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.